Illinois General Assembly - Full Text of SB2131
Illinois General Assembly

Previous General Assemblies

Full Text of SB2131  99th General Assembly




State of Illinois
2015 and 2016


Introduced 5/6/2015, by Sen. Dan Kotowski


225 ILCS 85/26

    Amends the Pharmacy Practice Act. Provides that pharmacists may not interchange an atypical anti-psychotic drug or targeted immune modulator without notification and documented consent by the prescribing practitioner and the patient or patient's parent, legal guardian, or spouse. Provides that if the pharmacist does substitute a drug, then the pharmacist shall provide written notice to the patient no later than the time the prescription is dispensed. Provides that these provisions shall not be construed to prohibit generic drug substitution as provided for in the Pharmacy Practice Act. Effective immediately.

LRB099 12255 MLM 35166 b





SB2131LRB099 12255 MLM 35166 b

1    AN ACT concerning regulation.
2    Be it enacted by the People of the State of Illinois,
3represented in the General Assembly:
4    Section 5. The Pharmacy Practice Act is amended by changing
5Section 26 as follows:
6    (225 ILCS 85/26)
7    (Section scheduled to be repealed on January 1, 2018)
8    Sec. 26. Anti-epileptic, atypical anti-psychotic, and
9targeted immune modulator (TIM) drug product change selection
11    (a) The General Assembly finds that this Section is
12necessary for the immediate preservation of the public peace,
13health, and safety.
14    (b) In this Section:
15    "Anti-epileptic drug" means (i) any drug prescribed for the
16treatment of epilepsy or (ii) a drug used to treat or prevent
18    "Epilepsy" means a neurological condition characterized by
19recurrent seizures.
20    "Seizure" means a brief disturbance in the electrical
21activity of the brain.
22    (c) When the prescribing physician has indicated on the
23original prescription "may not substitute", a pharmacist may



SB2131- 2 -LRB099 12255 MLM 35166 b

1not interchange an anti-epileptic drug or formulation of an
2anti-epileptic drug for the treatment of epilepsy, an atypical
3anti-psychotic drug, or targeted immune modulator (TIM)
4without notification and the documented consent of the
5prescribing practitioner physician and the patient or the
6patient's parent, legal guardian, or spouse. This Section does
7not apply to medication orders issued for anti-epileptic drugs,
8atypical anti-psychotic drugs, or targeted immune modulators
9for any in-patient care in a licensed hospital.
10    (d) If a pharmacist substitutes any generic prescription in
11place of any other a brand-name anti-epileptic drug, atypical
12anti-psychotic drug, or targeted immune modulator, then the
13pharmacist shall provide written notice to the patient no later
14than the time the prescription is dispensed.
15    (e) Nothing in this Section shall be construed to prohibit
16generic drug substitution as provided for in Section 25 of this
18(Source: P.A. 97-456, eff. 1-1-12.)
19    Section 99. Effective date. This Act takes effect upon
20becoming law.